Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00SBN
|
|||
| Former ID |
DAP000957
|
|||
| Drug Name |
Perhexiline
|
|||
| Synonyms |
Perhexilene; Perhexilina; Perhexilinum; Perhexilline; Perhexilina [INN-Spanish]; Perhexiline (INN); Perhexiline [INN:BAN]; Perhexilinum [INN-Latin]; (+)-2-(2,2-Dicyclohexylethyl)piperidine; (-)-2-(2,2-Dicyclohexylethyl)piperidine; 2-(2,2-Dicyclohexylethyl)piperidine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Angina pectoris [ICD-11: BA40; ICD-9: 413] | Approved | [1] | |
| Therapeutic Class |
Vasodilator Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H35N
|
|||
| Canonical SMILES |
C1CCC(CC1)C(CC2CCCCN2)C3CCCCC3
|
|||
| InChI |
1S/C19H35N/c1-3-9-16(10-4-1)19(17-11-5-2-6-12-17)15-18-13-7-8-14-20-18/h16-20H,1-15H2
|
|||
| InChIKey |
CYXKNKQEMFBLER-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 39648-47-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7703131, 8152912, 10532068, 11335717, 11360956, 11362767, 11365329, 11367891, 11372717, 11373824, 11376053, 11461928, 11466314, 11467434, 11485094, 11486147, 11489355, 11491394, 11491988, 11493827, 11533619, 14848632, 29223832, 46504471, 47588963, 47588964, 47662249, 47810720, 47810721, 47810722, 47885377, 48184966, 48416398, 49698937, 50065034, 53788212, 57288805, 78120409, 96025027, 103274161, 103858531, 104011326, 104307310, 124883588, 125823713, 127697988, 134338231, 134988277, 135265378, 135266783
|
|||
| ChEBI ID |
CHEBI:35553
|
|||
| ADReCS Drug ID | BADD_D01737 | |||
| SuperDrug ATC ID |
C08EX02
|
|||
| SuperDrug CAS ID |
cas=006621472
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides uniformis
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides uniformis was decreased by Perhexiline maleate (adjusted p-values: 4.55E-03). | |||
|
Studied Microbe: Prevotella copri
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Prevotella copri was decreased by Perhexiline maleate (adjusted p-values: 1.72E-04). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Coriobacteriales | ||||
|
Studied Microbe: Collinsella aerofaciens
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Collinsella aerofaciens was decreased by Perhexiline maleate (adjusted p-values: 1.92E-03). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Blautia obeum
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Blautia obeum was decreased by Perhexiline maleate (adjusted p-values: 3.46E-04). | |||
|
Studied Microbe: Clostridioides difficile
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Clostridioides difficile was decreased by Perhexiline maleate (adjusted p-values: 5.31E-03). | |||
|
Studied Microbe: Coprococcus comes
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Coprococcus comes was decreased by Perhexiline maleate (adjusted p-values: 1.12E-03). | |||
|
Studied Microbe: Dorea formicigenerans
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Dorea formicigenerans was decreased by Perhexiline maleate (adjusted p-values: 1.63E-03). | |||
|
Studied Microbe: Eubacterium eligens
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eubacterium eligens was decreased by Perhexiline maleate (adjusted p-values: 3.65E-05). | |||
|
Studied Microbe: Eubacterium rectale
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eubacterium rectale was decreased by Perhexiline maleate (adjusted p-values: 1.47E-03). | |||
|
Studied Microbe: Roseburia hominis
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Roseburia hominis was decreased by Perhexiline maleate (adjusted p-values: 1.65E-03). | |||
|
Studied Microbe: Roseburia intestinalis
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Roseburia intestinalis was decreased by Perhexiline maleate (adjusted p-values: 5.59E-04). | |||
|
Studied Microbe: Ruminococcus gnavus
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus gnavus was decreased by Perhexiline maleate (adjusted p-values: 1.60E-03). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Carnitine O-palmitoyltransferase I (CPT1B) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Fatty acid degradation | |||
| Fatty acid metabolism | ||||
| PPAR signaling pathway | ||||
| AMPK signaling pathway | ||||
| Adipocytokine signaling pathway | ||||
| Glucagon signaling pathway | ||||
| Pathwhiz Pathway | Fatty acid Metabolism | |||
| Reactome | RORA activates gene expression | |||
| PPARA activates gene expression | ||||
| Import of palmitoyl-CoA into the mitochondrial matrix | ||||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Mitochondrial LC-Fatty Acid Beta-Oxidation | ||||
| Nuclear Receptors Meta-Pathway | ||||
| PPAR Alpha Pathway | ||||
| Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | ||||
| Circadian Clock | ||||
| Fatty Acid Beta Oxidation | ||||
| AMPK Signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Perhexiline. Cardiovasc Drug Rev. 2007 Spring;25(1):76-97. | |||
| REF 2 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.